KevinMD July 5, 2024
It is no secret that we are making great strides in reducing the mortality of lung cancer. From improving screening rates which have reduced the chances of dying from lung cancer due to earlier detection, increased adoption of minimally invasive surgical techniques, and exciting new drugs that have been shown to improve survival even in metastatic disease, there is reason to be hopeful in what has usually been a devastating and fatal diagnosis. These newer drugs, such as immunotherapies and kinase inhibitors, typically require advanced molecular testing to help find the right drugs for a patient’s unique cancer, like finding the right key for a lock. Despite their proven efficacy, however, getting Medicare and other payors to pay for this...
Today's Sponsors
Today's Sponsor